Preservation solution, preservation system and method for preserving biological tissues in vitro, in particular corneal tissues
US-2024172743-A1 · May 30, 2024 · US
US12127553B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12127553-B2 |
| Application number | US-202217664194-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 19, 2022 |
| Priority date | Jan 31, 2017 |
| Publication date | Oct 29, 2024 |
| Grant date | Oct 29, 2024 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A cell cryopreservation method including adding a 1 volume % of a composition comprising 0.01 wt % to 20 wt % of a sophorose lipid to cells in a cell culture medium just before or up to 6 hours before cryopreserving the cells; and cryopreserving the cell culture medium, wherein the composition improves cell viability after cryopreservation compared to cells that are cryopreserved with a similar composition that does not contain the sophorose lipid.
Opening claim text (preview).
What is claimed is: 1. A cell cryopreservation method comprising: adding a 1 volume % of a composition comprising 0.01 wt % to 20 wt % of a sophorose lipid to cells in a cell culture medium just before or up to 6 hours before cryopreserving the cells; and cryopreserving the cell culture medium, wherein the composition improves cell viability after cryopreservation compared to cells that are cryopreserved with a similar composition that does not contain the sophorose lipid. 2. The method according to claim 1 , wherein the composition further comprises 5 wt % to 10 wt % of dimethyl sulfoxide (DMSO). 3. The method according to claim 2 , wherein a 10 volume % to 99 volume % of the composition is added to the cells. 4. The method according to claim 1 , wherein the composition further comprises 1 wt % to 50 wt % of a polyhydric alcohol. 5. The method of claim 4 , wherein the polyhydric alcohol comprises at least one of glycerin, ethylene glycol, and propylene glycol. 6. The method of claim 4 , wherein the composition does not contain dimethyl sulfoxide (DMSO). 7. The method of claim 4 , wherein the polyhydric alcohol is glycerin, and the cells are stem cells. 8. The method of claim 4 , wherein the stem cells are mesenchymal stem cells.
Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators · CPC title
Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood · CPC title
Bone marrow mesenchymal stem cells (BM-MSC) · CPC title
Preserving or maintaining viable microorganisms (immobilised microorganisms C12N11/00) · CPC title
DMSO · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.